for qrt pcr Roche Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Roche roche qrt pcr assay
    Expression of SMN2 mRNA in SMA patients and healthy controls. SMN2 mRNA was isolated from blood and analyzed using <t>qRT-PCR.</t> Expression level is calculated using 2ˆ-deltaCp of the reference gene. There is a strong overlap of SMN2 mRNA in the different patient groups. Note that in the healthy controls SMN2 levels are lower than levels in patients with the same SMN2 copy number.
    Roche Qrt Pcr Assay, supplied by Roche, used in various techniques. Bioz Stars score: 88/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/roche qrt pcr assay/product/Roche
    Average 88 stars, based on 10 article reviews
    Price from $9.99 to $1999.99
    roche qrt pcr assay - by Bioz Stars, 2020-04
    88/100 stars
      Buy from Supplier

    80
    Roche roche qrt pcr system
    Expression of SMN2 mRNA in SMA patients and healthy controls. SMN2 mRNA was isolated from blood and analyzed using <t>qRT-PCR.</t> Expression level is calculated using 2ˆ-deltaCp of the reference gene. There is a strong overlap of SMN2 mRNA in the different patient groups. Note that in the healthy controls SMN2 levels are lower than levels in patients with the same SMN2 copy number.
    Roche Qrt Pcr System, supplied by Roche, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/roche qrt pcr system/product/Roche
    Average 80 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    roche qrt pcr system - by Bioz Stars, 2020-04
    80/100 stars
      Buy from Supplier

    92
    Roche qrt pcr roche lightcycler 480 system
    Immune responses of CiIFN1/3 to plasmids containing CpG ODNs Left, the mRNA expressions of CiIFN1 (A) and CiIFN3 (B) were measured at 24 and 48 h post-infection. CIK cells were stimulated with PBS (control) or plasmids containing CpG ODNs and infected with GCRV. Other captions were the same as Figure 3 . Right, CIK cells were co-transfected with 800 ng of pRL-TK and IFN1pro-luc (A) or IFN3pro-luc (B) in 24-well plates. At 16 h post-transfection, the cells were stimulated with PBS (control) or plasmids and infected with GCRV for 16 h or uninfected. Dual luciferase reporter assays were conducted at 12 h after GCRV infection. Treatment durations in this assay was far shorter than those in <t>qRT-PCR</t> which caused different results. Error bars indicate standard deviation (n = 4). Asterisks indicate significant difference from control (*, P ≤ 0.05).
    Qrt Pcr Roche Lightcycler 480 System, supplied by Roche, used in various techniques. Bioz Stars score: 92/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/qrt pcr roche lightcycler 480 system/product/Roche
    Average 92 stars, based on 5 article reviews
    Price from $9.99 to $1999.99
    qrt pcr roche lightcycler 480 system - by Bioz Stars, 2020-04
    92/100 stars
      Buy from Supplier

    86
    Roche qrt pcr roche lightcycler technology
    ASPP2 mRNA expression in acute leukemia. <t>qRT-PCR</t> based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.
    Qrt Pcr Roche Lightcycler Technology, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/qrt pcr roche lightcycler technology/product/Roche
    Average 86 stars, based on 5 article reviews
    Price from $9.99 to $1999.99
    qrt pcr roche lightcycler technology - by Bioz Stars, 2020-04
    86/100 stars
      Buy from Supplier

    86
    Roche kapa sybr fast one step qrt pcr roche lightcycler
    ASPP2 mRNA expression in acute leukemia. <t>qRT-PCR</t> based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.
    Kapa Sybr Fast One Step Qrt Pcr Roche Lightcycler, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kapa sybr fast one step qrt pcr roche lightcycler/product/Roche
    Average 86 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    kapa sybr fast one step qrt pcr roche lightcycler - by Bioz Stars, 2020-04
    86/100 stars
      Buy from Supplier

    95
    Agilent technologies 2000c agilent bioanalyzer 2100 qrt pcr roche light cycler 480 pcr system
    ASPP2 mRNA expression in acute leukemia. <t>qRT-PCR</t> based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.
    2000c Agilent Bioanalyzer 2100 Qrt Pcr Roche Light Cycler 480 Pcr System, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 95/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/2000c agilent bioanalyzer 2100 qrt pcr roche light cycler 480 pcr system/product/Agilent technologies
    Average 95 stars, based on 18 article reviews
    Price from $9.99 to $1999.99
    2000c agilent bioanalyzer 2100 qrt pcr roche light cycler 480 pcr system - by Bioz Stars, 2020-04
    95/100 stars
      Buy from Supplier

    Image Search Results


    Expression of SMN2 mRNA in SMA patients and healthy controls. SMN2 mRNA was isolated from blood and analyzed using qRT-PCR. Expression level is calculated using 2ˆ-deltaCp of the reference gene. There is a strong overlap of SMN2 mRNA in the different patient groups. Note that in the healthy controls SMN2 levels are lower than levels in patients with the same SMN2 copy number.

    Journal: PLoS ONE

    Article Title: Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls

    doi: 10.1371/journal.pone.0139950

    Figure Lengend Snippet: Expression of SMN2 mRNA in SMA patients and healthy controls. SMN2 mRNA was isolated from blood and analyzed using qRT-PCR. Expression level is calculated using 2ˆ-deltaCp of the reference gene. There is a strong overlap of SMN2 mRNA in the different patient groups. Note that in the healthy controls SMN2 levels are lower than levels in patients with the same SMN2 copy number.

    Article Snippet: Comparison of Roche qRT-PCR assay on COBAS (SMN2 mRNA assay B) with SMN2 mRNA assay B ([ ]et al).

    Techniques: Expressing, Isolation, Quantitative RT-PCR

    Immune responses of CiIFN1/3 to plasmids containing CpG ODNs Left, the mRNA expressions of CiIFN1 (A) and CiIFN3 (B) were measured at 24 and 48 h post-infection. CIK cells were stimulated with PBS (control) or plasmids containing CpG ODNs and infected with GCRV. Other captions were the same as Figure 3 . Right, CIK cells were co-transfected with 800 ng of pRL-TK and IFN1pro-luc (A) or IFN3pro-luc (B) in 24-well plates. At 16 h post-transfection, the cells were stimulated with PBS (control) or plasmids and infected with GCRV for 16 h or uninfected. Dual luciferase reporter assays were conducted at 12 h after GCRV infection. Treatment durations in this assay was far shorter than those in qRT-PCR which caused different results. Error bars indicate standard deviation (n = 4). Asterisks indicate significant difference from control (*, P ≤ 0.05).

    Journal: Oncotarget

    Article Title: A plasmid containing CpG ODN as vaccine adjuvant against grass carp reovirus in grass carp Ctenopharyngodon idella

    doi: 10.18632/oncotarget.21245

    Figure Lengend Snippet: Immune responses of CiIFN1/3 to plasmids containing CpG ODNs Left, the mRNA expressions of CiIFN1 (A) and CiIFN3 (B) were measured at 24 and 48 h post-infection. CIK cells were stimulated with PBS (control) or plasmids containing CpG ODNs and infected with GCRV. Other captions were the same as Figure 3 . Right, CIK cells were co-transfected with 800 ng of pRL-TK and IFN1pro-luc (A) or IFN3pro-luc (B) in 24-well plates. At 16 h post-transfection, the cells were stimulated with PBS (control) or plasmids and infected with GCRV for 16 h or uninfected. Dual luciferase reporter assays were conducted at 12 h after GCRV infection. Treatment durations in this assay was far shorter than those in qRT-PCR which caused different results. Error bars indicate standard deviation (n = 4). Asterisks indicate significant difference from control (*, P ≤ 0.05).

    Article Snippet: qRT-PCR Roche LightCycler® 480 system was used to quantify the mRNA expression of the listed genes followed by their GenBank accession number: CiTLR9 (FJ969850), CiRIG-I (GQ478334), CiIFN1 (DQ357216), CiIFN3 (KU182642), CiIFNγ2 (AGQ16237), CiIL-2 (AF486820), CiIL-12 (KF944668), NFκB1 (nuclear factor-kappaB 1) (KY613788), NFκB2 (KY613789), VP4 (GQ469997), CiIgM (DQ417927), CiIgD (GQ429174), CiIgZ (GQ201421), CiTNF-α (HQ696609), CiMx2 (JF699168) and endogenous reference (EF1α, GQ266394 and 18S rRNA, EU047719) using BioEasy Master Mix (SYBR Green) (Hangzhou Bioer Technology Co., Ltd, China).

    Techniques: Infection, Transfection, Luciferase, Quantitative RT-PCR, Standard Deviation

    ASPP2 mRNA expression in acute leukemia. qRT-PCR based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.

    Journal: PLoS ONE

    Article Title: Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure

    doi: 10.1371/journal.pone.0080193

    Figure Lengend Snippet: ASPP2 mRNA expression in acute leukemia. qRT-PCR based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.

    Article Snippet: ASPP2 mRNA expression levels, relative to GAPD as the housekeeping gene, were determined by qRT-PCR Roche® LightCycler Technology (Roche, Basel, Switzerland).

    Techniques: Expressing, Quantitative RT-PCR